Cadila has received approval for its generic version of Lialda(Mesalaminedelayed release tablets) in the US (market size of USD 1.15 bn as per IMS)from its Moraiya facility. We expect this to be meaningful limited competition contributor (USD 130-140 mn in FY18/19 sales with ~80-85% gross margin)